WO2009054004A3 - Process for the preparation of sorafenib - Google Patents

Process for the preparation of sorafenib Download PDF

Info

Publication number
WO2009054004A3
WO2009054004A3 PCT/IN2008/000698 IN2008000698W WO2009054004A3 WO 2009054004 A3 WO2009054004 A3 WO 2009054004A3 IN 2008000698 W IN2008000698 W IN 2008000698W WO 2009054004 A3 WO2009054004 A3 WO 2009054004A3
Authority
WO
WIPO (PCT)
Prior art keywords
sorafenib
preparation
formula
novel
kinase
Prior art date
Application number
PCT/IN2008/000698
Other languages
French (fr)
Other versions
WO2009054004A2 (en
Inventor
Reddy Muddasani Pulla
Chowdary Nannapaneni Venkaiah
Original Assignee
Natco Pharma Ltd
Reddy Muddasani Pulla
Chowdary Nannapaneni Venkaiah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd, Reddy Muddasani Pulla, Chowdary Nannapaneni Venkaiah filed Critical Natco Pharma Ltd
Publication of WO2009054004A2 publication Critical patent/WO2009054004A2/en
Publication of WO2009054004A3 publication Critical patent/WO2009054004A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Abstract

A novel and improved process for the preparation of sorafenib (4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide) of formula (I) involving a novel intermediate of formula (II) as key intermediate is disclosed. Sorafenib tosylate, available in the market as Nexavar is a multiple kinase inhibitor targeting both RAF kinase and receptor tyrosine kinase that promote angiogenesis.
PCT/IN2008/000698 2007-10-22 2008-10-22 Process for the preparation of sorafenib WO2009054004A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2372CH2007 2007-10-22
IN2372/CHE/2007 2007-10-22

Publications (2)

Publication Number Publication Date
WO2009054004A2 WO2009054004A2 (en) 2009-04-30
WO2009054004A3 true WO2009054004A3 (en) 2009-07-02

Family

ID=40527499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000698 WO2009054004A2 (en) 2007-10-22 2008-10-22 Process for the preparation of sorafenib

Country Status (1)

Country Link
WO (1) WO2009054004A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (en) 1999-01-13 2002-10-15 バイエル コーポレイション ω-Carboxyaryl-substituted diphenylureas as p38 kinase inhibitors
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
DE602004011340T2 (en) 2003-05-20 2008-11-06 Bayer Healthcare Llc DIARYL-UREA SUBSTANCES WITH CHINESE-INHIBITING EFFECT
WO2011036647A1 (en) 2009-09-24 2011-03-31 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
AU2010299484A1 (en) 2009-09-24 2012-05-03 Ranbaxy Laboratories Limited Polymorphs of sorafenib acid addition salts
US8552197B2 (en) 2009-11-12 2013-10-08 Ranbaxy Laboratories Limited Sorafenib ethylsulfonate salt, process for preparation and use
US8618305B2 (en) 2010-01-29 2013-12-31 Ranbaxy Laboratories Limited Sorafenib dimethyl sulphoxide solvate
CN102190616B (en) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 A kind of deuterated synthesis of ω-diphenyl urea and the Method and process of production
CN103408488A (en) * 2013-08-13 2013-11-27 张家港威胜生物医药有限公司 Optimal synthetic method of sorafenib
DK3039424T3 (en) 2013-08-28 2020-08-31 Crown Bioscience Inc Taicang Gene expression signatures predictive of an individual's response to a multikinase inhibitor and methods of using them
CN104761492A (en) * 2014-01-03 2015-07-08 正大天晴药业集团股份有限公司 Crystal form of sorafenib tosylate, and preparation method thereof
CN104177292A (en) * 2014-08-08 2014-12-03 亿腾药业（泰州）有限公司 Method for industrial production of sorafenib tosylate polymorphic form I
CN105481764A (en) * 2014-09-16 2016-04-13 重庆圣华曦药业股份有限公司 Preparation method of sorafenib p-toluenesulfonate
CN105399668B (en) * 2015-12-29 2018-11-16 开封制药(集团)有限公司 A kind of method that " one kettle way " prepares Sorafenib
CN105801475B (en) * 2016-04-25 2018-01-12 华润双鹤利民药业（济南）有限公司 A kind of preparation method of Sorafenib Tosylate
CN109796400B (en) * 2017-11-16 2022-07-29 四川科伦药物研究院有限公司 Sorafenib tosylate crystal form and preparation method thereof
CN113395971A (en) 2019-01-31 2021-09-14 Ionis制药公司 Modulators of YAP1 expression

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0848078A (en) * 1994-08-05 1996-02-20 Nippon Paper Ind Co Ltd Heat-sensitive recorder
WO2000041698A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
WO2003068228A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
WO2006034796A1 (en) * 2004-09-29 2006-04-06 Bayer Healthcare Ag Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide
EP1683785A1 (en) * 2003-11-11 2006-07-26 Eisai Co., Ltd. Urea derivative and process for producing the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0848078A (en) * 1994-08-05 1996-02-20 Nippon Paper Ind Co Ltd Heat-sensitive recorder
WO2000041698A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
WO2003068228A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
EP1683785A1 (en) * 2003-11-11 2006-07-26 Eisai Co., Ltd. Urea derivative and process for producing the same
WO2006034796A1 (en) * 2004-09-29 2006-04-06 Bayer Healthcare Ag Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. BANKSTON ET AL.: "A Scalable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 6, no. 6, 2002, pages 777 - 781, XP002523918 *
PAN W ET AL: "Pyrimido-oxazepine as a versatile template for the development of inhibitors of specific kinases", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 15, no. 24, 15 December 2005 (2005-12-15), pages 5474 - 5477, XP025314229, ISSN: 0960-894X, [retrieved on 20051215] *

Also Published As

Publication number Publication date
WO2009054004A2 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
WO2009054004A3 (en) Process for the preparation of sorafenib
MY176929A (en) Thermodynamically stable form of a tosylate salt
TN2009000072A1 (en) 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl)]carbamoyl}amino)-3-fluorophenoxy}-n-methylpyridine-2-carboxamide monohydrate
HRP20170241T1 (en) Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
WO2009034308A3 (en) Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
UA85686C2 (en) Ethyl 3-(n-(2-(4-(hexyloxycarbonylamidino)ph enylaminomethyl)-1-methyl-1h-benzimidazole-5-carbonyl)-n-(2-pyridyl)a mino)propionate methanesulfonate, use thereof as a medicament and process for the preparation thereof
WO2011092663A3 (en) Sorafenib dimethyl sulphoxide solvate
WO2008059029A3 (en) New polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate
ATE516272T1 (en) 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDINE-2-ONE
CU20070069A7 (en) PROCESS FOR THE PREPARATION OF 4- {4- [CHLORINE-3- (TRIFLUOROMETIL) PHENYL] AMINO} CARBONYL) AMINO] PHENOXY} -N-METHYLPIRIDINE-2-CARBOXAMIDE
WO2007121432A3 (en) Benzoazepin-oxy-acetic acid derivatives as ppar-delta agonists used for the increase of hdl-c, lower ldl-c and lower cholesterol
FR2934280B1 (en) HOT, PRESSED PRESSING AND CUTTING DEVICE OF A HOT-STEEL SEMI-PRODUCT
TW200716107A (en) Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
ZA200804030B (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)benzamides and the salts thereof
WO2009134574A3 (en) Disubstituted phthalazine hedgehog pathway antagonists
WO2005123688A3 (en) 3-aminoindazoles
WO2012113873A3 (en) Organic compounds
RU2016102313A (en) BIARIAL DERIVATIVES AS GPR120 AGONISTS
WO2012066570A3 (en) Produce to produce etoricoxib
MX2010001938A (en) Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)p yrimidine-based compounds.
WO2008000745A3 (en) Adenosine derivatives for the treatment of pain
IN2014DN09941A (en)
HK1134670A1 (en) Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline 2-((4-(1--4-(-4-)-1h--3-)))
WO2009111785A3 (en) Treatment of sepsis with 5-ethyl-1-phenyl-2(1h)-pyridone and novel methods for synthesis
IL199239A0 (en) Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08841712

Country of ref document: EP

Kind code of ref document: A2